The Lancet Infectious Disease
Nov 2012 Volume 12 Number 11 p817 – 896
A case for control of cholera in Africa by vaccination
In The Lancet Infectious Diseases, Ahmed Khatib and colleagues1 describe the direct and indirect (herd protection) effectiveness of an oral killed Vibrio cholerae whole-cell B-subunit cholera vaccine deployed in a mass vaccination campaign in almost 50 000 individuals in Zanzibar, east Africa, a region that has had regular outbreaks of cholera since 1978. Two vaccine doses were offered and given through the public health services to individuals in the study areas aged 2 years and older. Over the next 14 months the vaccine was shown to confer 79% direct protection against cholera and also significant indirect protection (50% in the non-vaccinated residents and as much as 75–90% in clusters with the highest vaccine coverage).
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study
Ahmed M Khatib, Mohammad Ali, Lorenz von Seidlein, Deok Ryun Kim, Ramadhan Hashim, Rita Reyburn, Benedikt Ley, Kamala Thriemer, Godwin Enwere, Raymond Hutubessy, Maria Teresa Aguado, Marie-Paule Kieny, Anna Lena Lopez, Thomas F Wierzba, Said Mohammed Ali, Abdul A Saleh, Asish K Mukhopadhyay, John Clemens, Mohamed Saleh Jiddawi, Jacqueline Deen
Zanzibar, in east Africa, has been severely and repeatedly affected by cholera since 1978. We assessed the effectiveness of oral cholera vaccination in high-risk populations in the archipelago to estimate the indirect (herd) protection conferred by the vaccine and direct vaccine effectiveness.
We offered two doses of a killed whole-cell B-subunit cholera vaccine to individuals aged 2 years and older in six rural and urban sites. To estimate vaccine direct protection, we compared the incidence of cholera between recipients and non-recipients using generalised estimating equations with the log link function while controlling for potential confounding variables. To estimate indirect effects, we used a geographic information systems approach and assessed the association between neighbourhood-level vaccine coverage and the risk for cholera in the non-vaccinated residents of that neighbourhood, after controlling for potential confounding variables. This study is registered with ClinicalTrials.gov, number NCT00709410.
Of 48 178 individuals eligible to receive the vaccine, 23 921 (50%) received two doses. Between February, 2009, and May, 2010, there was an outbreak of cholera, enabling us to assess vaccine effectiveness. The vaccine conferred 79% (95% CI 47—92) direct protection against cholera in participants who received two doses. Indirect (herd) protection was shown by a decrease in the risk for cholera of non-vaccinated residents within a household’s neighbourhood as the vaccine coverage in that neighbourhood increased.
Our findings suggest that the oral cholera vaccine offers both direct and indirect (herd) protection in a sub-Saharan African setting. Mass oral cholera immunisation campaigns have the potential to provide not only protection for vaccinated individuals but also for the unvaccinated members of the community and should be strongly considered for wider use. Because this is an internationally-licensed vaccine, we could not undertake a randomised placebo-controlled trial, but the absence of vaccine effectiveness against non-cholera diarrhoea indicates that the noted protection against cholera could not be explained by bias.
Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and the South Korean Government.